KVP Capital Advisors, LP
13F Reported Value
ⓘ$133.9M
Holdings
32
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
KVP Capital Advisors, LP disclosed 32 positions worth $133.9M in its Form 13F-HR for Q1 2026, led by $TERN (Terns Pharmaceuticals, Inc.) at 17.3% of the equity portfolio, followed by $PRAX and $WHWK. During the quarter the fund opened 9 new positions and exited 4 — including a new stake in $STRO and a full exit from $JAZZ. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from KVP Capital Advisors, LP’s Form 13F-HR filing with the SEC under CIK 1858198.
Sector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$23.2M440,000 sh - $13.8M42,900 sh
- 9.6#2,816
Quality
$7.5M2,165,997 sh - 36.6
Quality
$6.1M36,200 sh - 30.1
Quality
$5.6M226,575 sh - 24.8
Quality
$5.6M53,000 sh - —
Quality
$5.5M340,000 sh - —
Quality
$4.9M414,000 sh - 26.9
Quality
$4.8M230,264 sh - 29.4
Quality
$4.7M28,497 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Terns Pharmaceuticals, Inc.$TERN | — | $23.2M | 440,000 |
 Praxis Precision Medicines, Inc.$PRAX | — | $13.8M | 42,900 |
 Whitehawk Therapeutics, Inc.$WHWK | 9.6#2,816 | $7.5M | 2,165,997 |
 Axsome Therapeutics, Inc.$AXSM | 36.6 | $6.1M | 36,200 |
 SUTRO BIOPHARMA, INC.$STRO | 30.1 | $5.6M | 226,575 |
 Protagonist Therapeutics, Inc$PTGX | 24.8 | $5.6M | 53,000 |
 Erasca, Inc.$ERAS | — | $5.5M | 340,000 |
 Trevi Therapeutics, Inc.$TRVI | — | $4.9M | 414,000 |
 Tango Therapeutics, Inc.$TNGX | 26.9 | $4.8M | 230,264 |
 INSMED Inc$INSM | 29.4 | $4.7M | 28,497 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of KVP Capital Advisors, LP's 32 positions.
Showing top 10 of 32 holdings.
Sector Allocation
Healthcare
$133.9M
Full Holdings — KVP Capital Advisors, LP (Q1 2026)
All 32 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $TERN | Terns Pharmaceuticals, Inc. | $23.2M | 17.3% | +0% | — |
| 2 | $PRAX | Praxis Precision Medicines, Inc. | $13.8M | 10.3% | +0% | — |
| 3 | $WHWK | Whitehawk Therapeutics, Inc. | $7.5M | 5.6% | +0% | 9.6 |
| 4 | $AXSM | Axsome Therapeutics, Inc. | $6.1M | 4.6% | +0% | 36.6 |
| 5 | $STRO | SUTRO BIOPHARMA, INC. | $5.6M | 4.2% | NEW | 30.1 |
| 6 | $PTGX | Protagonist Therapeutics, Inc | $5.6M | 4.2% | +0% | 24.8 |
| 7 | $ERAS | Erasca, Inc. | $5.5M | 4.1% | NEW | — |
| 8 | $TRVI | Trevi Therapeutics, Inc. | $4.9M | 3.7% | +0% | — |
| 9 | $TNGX | Tango Therapeutics, Inc. | $4.8M | 3.6% | NEW | 26.9 |
| 10 | $INSM | INSMED Inc | $4.7M | 3.5% | +0% | 29.4 |
| 11 |  $EWTX | Edgewise Therapeutics, Inc. | $4.2M | 3.1% | +0% | — |
| 12 |  $RVMD | Revolution Medicines, Inc. | $3.9M | 2.9% | +46% | — |
| 13 |  $IRON | Disc Medicine, Inc. | $3.7M | 2.8% | +0% | — |
| 14 |  $MBX | MBX Biosciences, Inc. | $3.6M | 2.7% | +0% | — |
| 15 |  $SVRA | Savara Inc | $3.3M | 2.5% | +0% | — |
| 16 |  $UTHR | UNITED THERAPEUTICS Corp | $2.8M | 2.1% | +0% | 80.1 |
| 17 |  $TVTX | Travere Therapeutics, Inc. | $2.7M | 2.0% | +0% | 39.2 |
| 18 |  $IDYA | IDEAYA Biosciences, Inc. | $2.7M | 2.0% | NEW | 10.5 |
| 19 |  $CMPX | Compass Therapeutics, Inc. | $2.6M | 2.0% | NEW | — |
| 20 |  $OCUL | OCULAR THERAPEUTIX, INC | $2.5M | 1.9% | NEW | 12.8 |
| 21 |  $VRDN | Viridian Therapeutics, Inc.\DE | $2.4M | 1.8% | NEW | 30.5 |
| 22 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $2.3M | 1.7% | NEW | — |
| 23 |  $ZURA | Zura Bio Ltd | $2.2M | 1.7% | NEW | — |
| 24 |  $SRRK | Scholar Rock Holding Corp | $2.2M | 1.6% | +0% | — |
| 25 |  $IMMX | Immix Biopharma, Inc. | $2.1M | 1.6% | +0% | — |
| 26 |  $SLNO | SOLENO THERAPEUTICS INC | $2.0M | 1.5% | +0% | 46.3 |
| 27 |  $NKTR | NEKTAR THERAPEUTICS | $1.9M | 1.4% | +0% | 10.2 |
| 28 |  $CABA | Cabaletta Bio, Inc. | $1.4M | 1.0% | +0% | — |
| 29 |  $ACHV | ACHIEVE LIFE SCIENCES, INC. | $1.4M | 1.0% | +0% | — |
| 30 |  $VERA | Vera Therapeutics, Inc. | $1.3M | 1.0% | +0% | — |
| 31 |  $CELC | Celcuity Inc. | $456,560 | 0.3% | +0% | — |
| 32 |  $VYNE | VYNE Therapeutics Inc. | $299,079 | 0.2% | +0% | — |
New Positions (9)
$STRO SUTRO BIOPHARMA, INC.$5.6M$ERAS Erasca, Inc.$5.5M$TNGX Tango Therapeutics, Inc.$4.8M$IDYA IDEAYA Biosciences, Inc.$2.7M$CMPX Compass Therapeutics, Inc.$2.6M$OCUL OCULAR THERAPEUTIX, INC$2.5M$VRDN Viridian Therapeutics, Inc.\DE$2.4M$DRUG BRIGHT MINDS BIOSCIENCES INC.$2.3M$ZURA Zura Bio Ltd$2.2M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for KVP Capital Advisors, LP including:
Track KVP Capital Advisors, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for KVP Capital Advisors, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: KVP Capital Advisors, LP
13F Pro is an AI hedge fund tracker and stock research platform. For KVP Capital Advisors, LP (SEC CIK: 1858198), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in KVP Capital Advisors, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.